2
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Structural Basis of Broad Ebolavirus Neutralization by a Human Survivor Antibody

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The structural features that govern broad-spectrum activity of broadly neutralizing, anti-ebolavirus antibodies (Abs) outside of the internal fusion loop epitope are currently unknown. Here we describe the structure of a broadly neutralizing human monoclonal Ab (mAb), ADI-15946, which was identified in a human survivor of the 2013–2016 outbreak. The crystal structure of ADI-15946 in complex with cleaved Ebola virus glycoprotein (EBOV GP CL) reveals that binding of the mAb structurally mimics the conserved interaction between the EBOV GP core and its glycan cap β17-β18 loop to inhibit infection. Both endosomal proteolysis of EBOV GP and binding of mAb FVM09 displace this loop, thereby increasing exposure of ADI-15946’s conserved epitope and enhancing neutralization. Our work also mapped the paratope of ADI-15946 thereby explaining reduced activity against Sudan virus (SUDV), which enabled rational, structure-guided engineering to enhance binding and neutralization against SUDV while retaining the parental activity against EBOV and Bundibugyo virus (BDBV).

          Related collections

          Most cited references27

          • Record: found
          • Abstract: found
          • Article: not found

          Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein.

          Using chemical inhibitors and small interfering RNA (siRNA), we have confirmed roles for cathepsin B (CatB) and cathepsin L (CatL) in Ebola virus glycoprotein (GP)-mediated infection. Treatment of Ebola virus GP pseudovirions with CatB and CatL converts GP1 from a 130-kDa to a 19-kDa species. Virus with 19-kDa GP1 displays significantly enhanced infection and is largely resistant to the effects of the CatB inhibitor and siRNA, but it still requires a low-pH-dependent endosomal/lysosomal function. These and other results support a model in which CatB and CatL prime GP by generating a 19-kDa intermediate that can be acted upon by an as yet unidentified endosomal/lysosomal enzyme to trigger fusion.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

            Ebola and Marburg filoviruses cause deadly outbreaks of haemorrhagic fever. Despite considerable efforts, no essential cellular receptors for filovirus entry have been identified. We showed previously that Niemann-Pick C1 (NPC1), a lysosomal cholesterol transporter, is required for filovirus entry. Here, we demonstrate that NPC1 is a critical filovirus receptor. Human NPC1 fulfills a cardinal property of viral receptors: it confers susceptibility to filovirus infection when expressed in non-permissive reptilian cells. The second luminal domain of NPC1 binds directly and specifically to the viral glycoprotein, GP, and a synthetic single-pass membrane protein containing this domain has viral receptor activity. Purified NPC1 binds only to a cleaved form of GP that is generated within cells during entry, and only viruses containing cleaved GP can utilize a receptor retargeted to the cell surface. Our findings support a model in which GP cleavage by endosomal cysteine proteases unmasks the binding site for NPC1, and GP-NPC1 engagement within lysosomes promotes a late step in entry proximal to viral escape into the host cytoplasm. NPC1 is the first known viral receptor that recognizes its ligand within an intracellular compartment and not at the plasma membrane.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain.

              We have determined the structure of GP2 from the Ebola virus membrane fusion glycoprotein by X-ray crystallography. The molecule contains a central triple-stranded coiled coil followed by a disulfide-bonded loop homologous to an immunosuppressive sequence in retroviral glycoproteins, which reverses the chain direction and connects to an alpha helix packed antiparallel to the core helices. The structure suggests that fusion peptides near the N termini form disulfide-bonded loops at one end of the molecule and that the C-terminal membrane anchors are at the same end. In this conformation, GP2 could both bridge two membranes and facilitate their apposition to initiate membrane fusion. We also find a heptad irregularity like that in low-pH-induced influenza HA2 and a solvent ion trapped in a coiled coil like that in retroviral TMs.
                Bookmark

                Author and article information

                Journal
                101186374
                31761
                Nat Struct Mol Biol
                Nat. Struct. Mol. Biol.
                Nature structural & molecular biology
                1545-9993
                1545-9985
                16 February 2019
                04 March 2019
                March 2019
                04 September 2019
                : 26
                : 3
                : 204-212
                Affiliations
                [1 ]Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California 92037
                [2 ]Department of Microbiology and Immunology, Albert Einstein College of Medicine, Bronx, New York 10461
                [3 ]Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555
                [4 ]Galveston National Laboratory, University of Texas Medical Branch, Galveston, Texas 77555
                [5 ]Division of Virology, United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Maryland 21702
                [6 ]Adimab LLC, Lebanon, New Hampshire 03766
                [7 ]Integrated Biotherapeutics, Rockville, Maryland 20850
                [8 ]Department of Immunology and Microbiology, University of Texas Medical Branch, Galveston, Texas 77555
                [9 ]Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, California 92037
                Author notes
                [10]

                Current Address: Adimab LLC, Lebanon, New Hampshire 03766

                [11]

                Current Address: Mapp Biopharmaceutical, San Diego, California 92121

                Author contributions:

                B.R.W., A.Z.W., C.L.M., M.L.F., P.A.I., K.H., A.S.W., R.M.J., A.S.H., S.H., E.G., K.A.H., and S.K. performed research. B.R.W., A.Z.W., K.C., and E.O.S. designed the study. M.J.A. contributed materials. L.M.W., J.M.D., A.B., K.C. and E.O.S. supervised research. B.R.W., A.ZW., K.C., and E.O.S. drafted the manuscript. B.R.W., A.Z.W., K.C. and E.O.S edited the manuscript, and all authors analyzed data and commented on the drafts.

                [* ]Correspondence and requests for materials should be addressed to E.O.S. ( erica@ 123456scripps.edu ) and K.C. ( kartik.chandran@ 123456einstein.yu.edu )
                Article
                NIHMS1519500
                10.1038/s41594-019-0191-4
                6402988
                30833785
                6f43412c-4985-46bf-8a5f-4861e890270d

                Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms

                History
                Categories
                Article

                Molecular biology
                Molecular biology

                Comments

                Comment on this article